Accelerating Patient Access: The Progress and Possibilities of Innovative Payment Models in Canada

Recent developments in frameworks and processes to support timely patient access to novel therapies have been noteworthy, including Canada’s Drug Agency’s (CDA) Time-Limited Recommendation Category, the pan-Canadian Pharmaceutical Alliance’s (pCPA) Temporary Access Process, and Institut national d'excellence en santé et services sociaux’s (INESSS) Alternative Economic Scenarios. As such, there is a growing interest and discussion among Canadian stakeholders regarding innovative approaches and models – such as managed access schemes and outcomes-based agreements. However, a lack of clarity surrounding these concepts may be hindering effective progress within the Canadian landscape.

As a passionate advocate for accelerating patient access to novel health technologies, the Resilient Healthcare Coalition (RHC) is delighted to be collaborating with Allison Wills, Partner at 20Sense, on June 12. Allison will open the discussion highlighting the promising role of innovative payment models by evaluating their current state in Canada and then identifying necessary steps to advance timely patient access to novel therapies.

This will lead to insightful inputs from expert panelists, including Nicole Mittmann, Chief Scientist and Vice President, Scientific Evidence, Methodologies and Resources at the Canada’s Drug Agency (CDA); Raelynn Douglas, Executive Director, Drug Plan at the Ministry of Health, Government of Saskatchewan, Lisa Machado, Lived Experience Advocate, Journalist, and Founder of The Canadian CML Network, and Andrea Masters, Strategic Access and Pricing Director at Roche Canada.

This webinar will not only clarify the definitions and details of managed access frameworks and outcomes-based agreements but also dive into the significance, progress, and future possibilities of these approaches across Canada